Reinventing Life Science Startups–Therapeutics and Diagnostics
Steve Blank
AUGUST 19, 2013
has gone offshore primarily due to the toughened regulatory environment. It has gotten so bad that pension funds and other institutional investors in venture capital funds have told these funds to stay away from Life Science – or at the least, early stage Life Science. Pharma companies are staggering under the costs.
Let's personalize your content